Therapy News and Research

RSS

Medarex announces preliminary data for investigational anti-PD-1 antibody

Medarex, Inc. has announced preliminary data from an ongoing Phase 1 study of MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human anti-PD-1 antibody.

2 Jun 2008

BiPar Sciences presents data for novel DNA repair inhibitor

BiPar Sciences, Inc. today announced the results of first-in-human clinical studies of its lead product, BSI-201, in patients with solid tumors.

2 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

For the past 70 years the treatment of choice for advanced, metastatic prostate cancer has been androgen-deprivation therapy. That is, the suppression of circulating testosterone - the hormone that fuels prostate-cancer growth - via surgical castration (orchiectomy) or medical castration with testosterone-blocking drugs. While such therapy buys time for patients, it is not a cure, as inevitably the cancer becomes resistant to the androgen deprivation and continues to grow.

2 Jun 2008

Survivors of childhood Hodgkin's lymphoma at higher risk of future health problems

Adults who survived childhood Hodgkin's Lymphoma should be especially vigilant about cancer and cardiovascular screenings, according to researchers from Wake Forest University Baptist Medical Center and colleagues.

2 Jun 2008

3 million now receiving anti-retroviral therapy HIV drugs

The close of 2007 marks an important step in the history of the HIV/AIDS epidemic. Nearly 3 million people are now receiving anti-retroviral therapy (ART) in low- and middle-income countries, according to a new report jointly launched today by WHO, UNAIDS and UNICEF.

2 Jun 2008

Potential hypophosphatasia therapy discovered

Researchers at the Burnham Institute for Medical Research, led by José Luis Millán, Ph.D., have demonstrated in mice the first successful use of enzyme replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal disease of genetic origin. This discovery lays the foundation for future clinical trials for HPP patients.

1 Jun 2008

Survivors of childhood Hodgkin's lymphoma at higher risk of future health problems

1 Jun 2008

Young age may provide survival advantage to children with certain brain tumors

St. Jude Children's Research Hospital investigators have shown that children under 3 years old who have a brain tumor called diffuse pontine glioma (DPG) appear to have a better outcome than older children with the same cancer.

1 Jun 2008

Acupuncture reduces pain and dysfunction in head and neck cancer patients after neck dissection

New data from a randomized, controlled trial found that acupuncture provided significant reductions in pain, dysfunction, and dry mouth in head and neck cancer patients after neck dissection. The study was led by David Pfister, MD, Chief of the Head and Neck Medical Oncology Service, and Barrie Cassileth, PhD, Chief of the Integrative Medicine Service, at Memorial Sloan-Kettering Cancer Center (MSKCC). Dr. Pfister presented the findings today at the annual meeting of the American Society for Clinical Oncology.

1 Jun 2008

Combination biotherapies safe, promising for melanoma patients

The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

1 Jun 2008

How advanced prostate cancer becomes resistant to androgen-deprivation therapy

1 Jun 2008

Self-assembled viruses

Viruses are true experts at importing genetic material into the cells of an infected organism. This trait is now being exploited for gene therapy, in which genes are brought into the cells of a patient to treat genetic diseases or genetic defects. Korean researchers have now made an artificial virus. As described in the journal Angewandte Chemie, they have been able to use it to transport both genes and drugs into the interior of cancer cells.

30 May 2008

University of Bristol to test effectiveness of cognitive behavioural therapy

A team of researchers, led by Dr Nicola Wiles at the University of Bristol, has been awarded £1.2 million by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme for a clinical trial to investigate the effectiveness of cognitive behavioural therapy (CBT) for patients with depression who do not respond to treatment with antidepressants.

30 May 2008

Post-menopausal therapy to improve women's quality of life

A recent research work by the University of Granada advises post-menopausal women the use of Replacement Hormone Therapy (RHT) for at least five years.

29 May 2008

Rett syndrome gene found to be full of surprises

A study funded by the National Institutes of Health (NIH) has transformed scientists' understanding of Rett syndrome, a genetic disorder that causes autistic behavior and other disabling symptoms. Until now, scientists thought that the gene behind Rett syndrome was an "off" switch, or repressor, for other genes. But the new study, published today in Science, shows that it is an "on" switch for a startlingly large number of genes.

29 May 2008

Cancer survivors are living "in limbo" with unmet needs for care

Many long-term survivors of cancer are not receiving the necessary symptom management that they require to help them live with the consequences of their disease, its treatment, or both, according to a leading professor of palliative medicine.

28 May 2008

San Francisco Mayor rejects proposed budget cuts to HIV/AIDS services

San Francisco Mayor Gavin Newsom recently rejected proposed cuts to HIV/AIDS services in his fiscal year 2009 budget, the San Francisco Chronicle reports. According to the Chronicle, Newsom rejected a proposal by Mitch Katz, director of the San Francisco Department of Public Health, to cut $3 million of the $10 million the department allocates to 30 not-for-profit groups that provide HIV/AIDS services.

28 May 2008

Magnetic nanoparticles for cancer therapy

A measuring procedure developed in the Physikalisch-Technische Bundesanstalt (PTB) can help to investigate in some detail the behaviour of magnetic nanoparticles which are used for cancer therapy.

28 May 2008

Estrogen drives distinct, aggressive prostate cancer

Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.

28 May 2008

First patient enrolled in phase III study of Bevacizumab and Trastuzumab in early breast cancer

A new international study for women with HER2-positive breast cancer is open for enrollment. The pivotal BETH (BEvacizumab and Trastuzumab Adjuvant Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial that is investigating the benefits of combining two monoclonal antibodies, the anti-angiogenic, bevacizumab (Avastin) and the targeted therapy trastuzumab (Herceptin), together with chemotherapy for the treatment of patients with early stage HER2-positive breast cancer.

27 May 2008